About
SOMAVAC® Medical Solutions, Inc. is a MedTech company developing and pioneering new technology platforms to mitigate surgical complications, improve treatment protocols, and reduce the overall cost of healthcare.
Our platforms are led by our patented SOMAVAC® Deep Tissue Negative Pressure Therapy which is the first powered negative pressure therapy device cleared for seroma prophylaxis. For patients undergoing breast reconstruction and/or mastectomies, negative pressure delivered by SOMAVAC® removes fluid as it is produced, obliterates dead space, and holds tissues together which have been shown to prevent seromas. Seromas can lead to surgical complications like surgical site infections, wound dehiscence, etc. SOMAVAC® is FDA cleared for seroma prophylaxis.
Memphis